GSK signed a 12-asset licensing deal with Hengrui Pharma. Generic erosion on Vyvanse continued to hurt Takeda. Celltrion is ...

As patent cliffs approach and new mechanisms gain ground, COPD drugs like HRS-9821 are fast becoming coveted assets.

Out-licensing drugs to multinational corporations is a natural step for Chinese biotechs, but the recent rise in deals is ...

These 10 stocks could mint the next wave of millionaires › IDEAYA Biosciences (NASDAQ:IDYA), a precision oncology company focused on developing targeted therapies for cancer, reported its ...

The demand for treatments targeting myeloproliferative disorders is rising sharply, propelled by several key factors that underscore the market's rob ...

Roche gambled on an all-comer design for trials of its COPD candidate astegolimab, a move that may prove costly as it fails a phase 3 test.

Melbourne-based biotech VC Boson Ventures has raised $10 million of a target $30 million fund and is positioning itself as a ...

Bengaluru: British drugmaker GSK expects annual sales and profit to be towards the top of its forecast range, after ...

Deal with DoveTree, established by Harvard professor Gregory Verdine, adds to growing list of licensing tie-ups with Chinese ...

The market for chronic obstructive pulmonary disease treatment devices is projected to witness substantial growth, fueled by ...

GSK's drug for severe itching in patients with autoimmune liver disease PBC is now under review in the EU and US, as Mirum Pharma tries to catch up.